Traprostinil-iloprost combination therapy

By inhaling the composition of iloprost and troprosteneil, the problem that existing pulmonary hypertension treatment methods cannot effectively reduce pulmonary arterial pressure and improve exercise capacity is solved, achieving dual benefits for the heart and pulmonary blood vessels, significantly reducing symptoms.

CN118984697AActive Publication Date: 2024-11-19UNITED THERAPEUTICS CORP
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202380032526.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-08
Filing Date
2023-02-07
Publication Date
2024-11-19
Estimated Expiration
2043-02-07

AI Technical Summary

Technical Problem

Existing treatments for pulmonary hypertension are difficult to effectively reduce pulmonary arterial pressure and improve patients' motility, and single drug therapy cannot provide dual benefits of heart and pulmonary vascularity.

Method used

By inhaling the composition of iloprost and traprostellil, combined with its pharmaceutically acceptable salt or ester, administered to the patient, ensuring that the dosage of iloprost is at least 2.5 μg and the dosage of traprostellil is at least 2.5 μg and the dosage of traprostellil is at least 300 μg. 5μg to exert the effects of pulmonary vasodilation and cardiac muscle strength enhancement.

Benefits of technology

This method can significantly reduce pulmonary arterial pressure, improve exercise ability, reduce symptoms such as shortness of breath and fainting, and provide dual benefits of heart and pulmonary blood vessels, surpassing the effects of single drug therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984697A_ABST
    Figure CN118984697A_ABST
Patent Text Reader

Abstract

The present disclosure relates to the treatment of diseases, such as pulmonary hypertension, by inhalation of a combination of iloprost and treprostinil.
Need to check novelty before this filing date? Find Prior Art

Description

Related Applications

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 307,919, filed on February 8, 2022, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present application generally relates to compositions comprising prostacyclin and methods of using prostacyclin to treat disease, including compositions comprising treprostinil and iloprost and methods of using combinations comprising treprostinil and iloprost to treat disease. Summary of the invention

[0003] One embodiment is a method of treating pulmonary hypertension comprising administering by inhalation to a subject in need thereof iloprost or a pharmaceutically acceptable salt thereof and treprostinil or a pharmaceutically acceptable salt thereof.

[0004] Another embodiment is a method of treating pulmonary hypertension comprising administering to a subject in need thereof a composition comprising (i) iloprost or a pharmaceutically acceptable salt thereof and (ii) treprostinil or a pharmaceutically acceptable salt thereof in a single event dose by inhalation, wherein the dose of iloprost or a pharmaceutically acceptable salt thereof delivered to the subject is at least 2.5 μg and the dose of treprostinil or a pharmaceutically acceptable salt thereof delivered to the subject is at least 5 μg. BRIEF DESCRIPTION OF THE DRAWINGS

[0005] The figure shows the chromatograms of iloprost soluble solutions at different pH levels (arbitrary units and minutes). DETAILED DESCRIPTION

[0006] As used herein and in the claims, the singular forms "a", "an", and "said / the" include the plural, unless the context clearly indicates otherwise. Throughout the specification, unless otherwise indicated, "include", "comprise", and "contain" are all used inclusively rather than exclusively, and therefore, a designated integer or group of integers may include one or more other undesignated integers or groups of integers. The term "or" is inclusive, unless modified, for example, by "either". Therefore, unless the context indicates otherwise, the term "or" refers to any one member of a particular list, and also includes any combination of members in that list. "Consisting of..." should refer to trace elements and substantial method steps excluding other ingredients. The embodiments defined by each of these transitional terms belong to the scope of the present technology. When an embodiment is defined by one of these terms (such as "comprising"), it should be understood that the present disclosure also includes alternative embodiments, such as "essentially consisting of the embodiment" and "consisting of the embodiment".

[0007] All numerical designations, such as amounts, times and concentrations, including ranges, are approximate and vary (+) or (-) in increments of 0.05%, 1%, 2%, 5%, 10% or 20%. It should be understood, although not always explicitly stated, that all numerical designations are preceded by the term "about".

[0008] "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the subject of treatment, observation, or experiment. Unless otherwise indicated, "subject" and "patient" can be used interchangeably. The methods described herein can be used for human therapy and / or veterinary applications. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

[0009] Where a numerical range is provided, each intervening value (one tenth of a unit of the lower limit) between the upper and lower limits of the range and any other specified value or intervening value in the specified range is included in the present technology unless the context clearly dictates otherwise. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also included in the present technology, but are limited by any explicitly excluded limits in the specified ranges. When the specified range includes one or both of the limits, ranges excluding one or both of these limits are also included in the present technology.

[0010] "Pulmonary hypertension" ("PH") refers to all forms of pulmonary hypertension, including all pulmonary hypertension included in WHO groups 1-5, unless otherwise specified or apparent to one of ordinary skill in the art. Pulmonary hypertension (PH) is a condition characterized by increased blood pressure in the pulmonary arteries. Symptoms of PH may include one or more of shortness of breath, fainting, fatigue, chest pain, leg swelling, and rapid heartbeat. "Pulmonary hypertension" includes all forms of pulmonary arterial hypertension ("PAH") (Group 1), including idiopathic and hereditary PAH. Pulmonary hypertension includes patients with NYHA functional class III symptoms. "Pulmonary hypertension" includes pulmonary hypertension caused by left heart disease (Group 2). "Pulmonary hypertension" includes pulmonary hypertension caused by lung disease (Group 3). "Pulmonary hypertension" includes thromboembolic pulmonary hypertension (Group 4). "Pulmonary hypertension" includes pulmonary hypertension secondary to other conditions such as sarcoidosis, sickle cell anemia, chronic hemolytic anemia, splenectomy, and certain metabolic disorders (Group 5). In general, the treatment approaches described herein are most applicable to PAH (Group 1) and Group 3 PH, including PH-ILD.

[0011] One embodiment is a method for treating pulmonary hypertension, which applies a combination of iloprost and treprostinil to a subject (preferably a person suffering from pulmonary hypertension) by inhalation. As a substitute or supplement for treprostinil or iloprost, a pharmaceutically acceptable salt or ester or prodrug can be applied. For example, the sodium salt of iloprost and treprostinil can be applied to treat pulmonary hypertension. Unless otherwise indicated, reference to treprostinil and iloprost herein includes pharmaceutically acceptable salts, esters and prodrugs of these compounds.

[0012] Iloprost (trade name: Ilomedine is used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, and other diseases in which blood vessels constrict and blood cannot flow to tissues. Iloprost was developed by pharmaceutical company Schering AG and is marketed in Europe by Bayer Schering Pharma AG and in the United States by Actelion Pharmaceuticals. Iloprost is a synthetic analog of prostacyclin PGI2 and has the following structure: In the United States, iloprost The solution is approved for inhalation via the I-Neb AAD or Prodose AAD delivery systems. In Europe, iloprost as Ventavis has been approved for use with two compressed air nebulizers with AAD delivery systems (Halolite and Prodose) and two ultrasonic nebulizers, Ventaneb and I-Neb.

[0013] Treprostinil can also be used to treat pulmonary hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2) with the following structure:

[0014] (Treprostinil) injection, (treprostinil) inhalation solution and Treprostinil, the active ingredient of the extended-release tablet, has been described in U.S. Pat. No. 4,306,075. For example, Moriarty, et al., J. Org. Chem. 2004, 69, 1890-1902, Drug of the Future, 2001, 26 (4), 364-374, U.S. Pat. Nos. 6,441,245, 6,528,688, 6,700,025, 6,809,223, 6,756,117, 8,461,393, 8,481,782; 8,242,305, 8,497,393, 8,940,930, 9,029,607, 9,156,786 and 9,388,154 9,346,738; U.S. Published Patent Application Nos. 2012-0197041, 2013-0331593, 2014-0024856, 2015-0299091, 2015-0376106, 2016-0107973, 2015-0315114, 2016-0152548, and 2016-0175319; PCT Publication Nos. WO2016 / 0055819 and WO2016 / 081658 describe methods for preparing treprostinil and other prostacyclin derivatives.

[0015] For example, U.S. Patent Nos. 5,153,222, 5,234,953, 6,521,212, 6,756,033, 6,803,386, 7,199,157, 6,054,486, 7,417,070, 7,384,978, 7,879,909, 8,563,614, 8,252,839, 8,536,363, 8,410,169, 8,232,316, 8,609,728, 8,350,079, 8,349,892. 、7,999,007、8,658,694、8,653,137、9,029,607、8,765,813、9,050,311、9,199,908、9,278,901、8,747,897、9,358,240、9,339,507、9,255,064、9,278,902、9,278,903、9,758,465;9,422,223;9,878,972;9,624,156、8,969, 409, 10,716,793, 10,376,525; U.S. Published Patent Application Nos. 2009-0036465, 2008-0200449, 2008-0280986, 2009-0124697, 2014-0275616, 2014-0275262, 2013-0184295, 2014-0323567, 2016-0030371, 2016-0051505, 2016-0030355, 2016-0143 Various other uses and / or forms of treprostinil are disclosed in WO00 / 57701, WO20160105538, WO2016038532, WO2018 / 058124, and WO2021 / 211916.

[0016] A "prodrug" of treprostinil refers to a compound that is converted in vivo to treprostinil or a pharmaceutically active derivative thereof, or PCT Publication No. WO2005 / 007081; U.S. Patent Nos. 7,384,978, 7,417,070, 7,544,713, 8,252,839, 8,410,169, 8,536,363, 9,050,311, 9,199,90 8, 9,278,901, 9,422,223; 9,624,156, 9,878,972, 9,371,264, 9,394,227, 9,505,737, 9,758,465, 9,643,911, 9,701,616, 9,776,982, 9,845,305, 9,957,200, 10,494,327 、10,053,414、10,246,403、10,344,012、10,450,290、10,464,877、10,464,878、10,703,706、10,752,733、9,255,064、9,469,600、10,010,518、10,343,979、10,526,274; Compounds described in U.S. Patent Application Publication Nos. 2018-0153847; 2021-0054009; 2021-0378996; U.S. Patent Application No. 17 / 549,573 filed on December 13, 2021; and U.S. Provisional Patent Application No. 63 / 156,110 filed on March 3, 2021, the entire contents of each of which are incorporated herein by reference.

[0017] "Pharmaceutically acceptable salts" are physiologically acceptable salts of treprostinil, treprostinil prodrugs or iloprost, as well as non-physiologically acceptable salts of treprostinil, treprostinil prodrugs or iloprost. Pharmaceutically acceptable salts of treprostinil, treprostinil prodrugs or iloprost fall within the scope of the present technology, including base addition salts that retain the desired pharmacological activity and are not biologically undesirable (e.g., the salt is not overly toxic, allergic or irritating, and is bioavailable). Treprostinil, treprostinil prodrugs or iloprost have at least one acidic group, such as a carboxylic acid group. Therefore, treprostinil, treprostinil prodrugs or iloprost can be combined with metals such as alkali metals or alkaline earth metals (such as Na + , Li + , K + , Ca 2+ Mg 2+ 、Zn 2+), ammonia or organic amines (such as dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, tromethamine) or basic amino acids (such as arginine, lysine, histidine and ornithine) to form salts. These salts can be prepared in situ during the isolation and purification of the compounds, or the purified free acid form of the compound can be reacted with a suitable base and the salt thus formed can be isolated.

[0018] Treatment can improve one or more physiological indicators associated with PH, or alleviate or reduce one or more symptoms associated with PH. For example, in some embodiments, treatment can reduce pulmonary artery pressure. In other embodiments, treatment can improve exercise capacity, such as improving the distance of a six-minute walk test (6MWT). In some embodiments, treatment can alleviate or reduce more than one symptom of PH, such as reducing shortness of breath or fainting.

[0019] In some embodiments, the combination of iloprost and treprostinil can be administered by inhalation to treat pulmonary arterial hypertension (PAH). PAH is characterized by thickening (narrowing of the lumen) and hardening of the pulmonary arteries. Therefore, the right side of the heart may have to work harder to push blood through these narrowed arteries. This extra pressure can cause the heart to lose the ability to pump enough blood through the lungs to meet the needs of the rest of the body.

[0020] In some embodiments, the combination of iloprost and treprostinil can be administered by inhalation to treat pulmonary hypertension, WHO Group 3, i.e., pulmonary hypertension due to a condition selected from chronic lung disease and / or hypoxia (low oxygen levels). Group 3 PH can be pulmonary hypertension associated with interstitial lung disease (PH-ILD).

[0021] Chronic lung disease can include obstructive lung disease, in which the airways in the lungs narrow and make it difficult to breathe out, such as chronic obstructive pulmonary disease (COPD) and emphysema; restrictive lung disease, in which the lungs have trouble expanding when you breathe in, such as interstitial lung disease or pulmonary fibrosis; sleep apnea; living at high altitudes for a long time; and various combinations of these conditions.

[0022] In some embodiments, the chronic lung disease may include idiopathic interstitial pneumonia, such as idiopathic pulmonary fibrosis, idiopathic nonspecific interstitial pneumonia, respiratory bronchiolitis (e.g., respiratory bronchiolitis associated with interstitial lung disease), desquamative interstitial pneumonia, acute interstitial pneumonia; chronic hypersensitivity pneumonitis, occupational lung disease, pulmonary fibrosis, emphysema, connective tissue disease, or any combination of the above conditions.

[0023] Treprostinil or a pharmaceutically acceptable salt thereof and iloprost or a pharmaceutically acceptable salt thereof may be administered in a therapeutically effective amount, which may be an amount effective for treating pulmonary hypertension.

[0024] Although the present invention is not bound by any theory, treprostinil is effective for pulmonary hypertension (such as pulmonary arterial hypertension or pulmonary hypertension associated with interstitial lung disease), at least in part due to its beneficial vasodilatory effect on pulmonary vasculature and / or its ability to induce pulmonary vascular remodeling. The half-life of iloprost is shorter than that of treprostinil. Since the half-life of iloprost is shorter, it is also usually administered more frequently. However, iloprost has a more substantial inotropic effect than treprostinil, which is beneficial to cardiac function. Combining the effects of treprostinil and / or iloprost on pulmonary vasculature with the relatively short but substantial inotropic effect of iloprost on the right heart can bring additional benefits to some patients with pulmonary hypertension, which cannot be provided when either drug is administered as a monotherapy. For example, a combination of treprostinil and iloprost can be administered as needed (i.e., as needed) to a patient with at least one undesirable symptom of pulmonary hypertension (such as dyspnea or shortness of breath). The iloprost in this combination may provide a relatively brief but substantial inotropic effect, which may reduce or ameliorate at least one undesirable symptom of pulmonary hypertension, such as dyspnea or shortness of breath.

[0025] In some embodiments, the iloprost administered by inhalation in combination with treprostinil may be iloprost as the free acid or iloprost tromethamine. In some embodiments, the treprostinil administered by inhalation in combination with iloprost may be treprostinil as the free acid or treprostinil sodium.

[0026] In some embodiments, iloprost and treprostinil can be administered simultaneously. For example, the patient can use any suitable delivery mechanism, such as a nebulizer or dry powder inhaler, to administer both iloprost and treprostinil. Simultaneous delivery can also be administered using a composition comprising treprostinil and iloprost. A skilled person can select the relative amounts of treprostinil and iloprost according to the desired dose, which will be discussed in more detail below. In some embodiments, simultaneous administration is achieved using a device of a rescue inhaler type that can deliver a fixed amount of medicine or set an upper limit on the deliverable dose.

[0027] In other embodiments, iloprost and treprostinil can be administered separately. These embodiments can be used to adjust the relative dose of the drug. For example, treprostinil can be administered before or after the administration of iloprost. The same or different delivery mechanisms can be used to administer the drug. The same or different inhalation devices can be used to administer the drug. For example, in some embodiments, a nebulizer can be used to administer one drug and a dry powder inhaler can be used to administer another drug. When iloprost and treprostinil are administered separately, the administration can be immediate, for example, iloprost is administered immediately after treprostinil is administered (or vice versa), or separated in time, for example, iloprost is administered after treprostinil is administered (or vice versa). For example, the administration of iloprost and treprostinil can be spaced about 2 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours or 4 hours. In some embodiments, the drug is administered at different frequencies. For example, treprostinil can be administered once, twice, three times or four times a day, and iloprost can be administered four times, five times, six times or more than six times a day. In some embodiments, one of the drugs (eg, iloprost) is administered on an as-needed basis and the other drug is administered according to a fixed dose regimen, such as once, twice, three times, or four times per day.

[0028] In some embodiments, the administration of iloprost and treprostinil can be performed in a single administration event or a single dose event. In some embodiments, the number of breaths in a single administration event or a single dose event should not exceed 20 breaths (or inhalations) or 19 breaths (or inhalations) or 18 breaths (or inhalations) or 17 breaths (or inhalations) or 16 breaths (or inhalations) or 15 breaths (or inhalations) or 14 breaths (or inhalations) or 13 breaths (or inhalations) or 12 breaths (or inhalations) or 11 breaths (or inhalations) or 10 breaths (or inhalations) or 9 breaths (or inhalations) or 8 breaths (or inhalations) or 7 breaths (or inhalations) or 6 breaths (or inhalations) or 5 breaths (or inhalations) or 4 breaths (or inhalations) or 3 breaths (or inhalations) or 2 breaths (or inhalations) or 1 breath (or inhalation).

[0029] The number of single administration events of treprostinil, its prodrug, its pharmaceutically acceptable salt, or its pharmaceutically acceptable salt of a prodrug administered by inhalation per day can vary. For example, the number of single administration events per day can be 1, 2, 3, 4, 5, or 6 times per day. In some embodiments, the number of single administration events per day can be at least two, such as 2 to 5 events per day or 2 to 3 events per day.

[0030] In a single administration event, the dose or amount of treprostinil, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable salt of its prodrug administered by inhalation can vary. In some embodiments, the single administration event dose of treprostinil can be at least 5 μg or at least 6 μg. In some embodiments, the single administration event dose of treprostinil can be 5 μg to 120 μg, or 18 μg to 120 μg, or 6 μg to 96 μg, or 7.5 μg to 100 μg, or 10 μg to 100 μg, or 15 μg to 100 μg, or 15 μg to 90 μg, or 15 μg to 75 μg, or 30 μg to 75 μg, or any value or sub-range within these ranges.

[0031] In a single administration event, the dose or amount of iloprost or its pharmaceutically acceptable salt administered by inhalation can vary. In some embodiments, the single administration event dose of iloprost can be at least 2 μg or at least 2.5 μg. In some embodiments, the single administration event dose of iloprost can be 2 μg to 10 μg, or 2 μg to 9 μg, or 2.5 μg to 5 μg, or any value or sub-range within these ranges. In some embodiments, the daily dose of iloprost administered in all administration events of a single day can be less than 15 μg, or not more than or less than 14 μg, or not more than or less than 13 μg, or not more than or less than 12 μg, or not more than or less than 11 μg, or not more than or less than 10 μg, or not more than or less than 9 μg, or not more than or less than 8 μg, or not more than or less than 7 μg, or not more than or less than 6 μg, or not more than or less than 5 μg.

[0032] In some embodiments, iloprost and treprostinil may be administered via a single inhalation device, such as a nebulizer or dry powder inhaler, which may contain two separate compositions, one containing iloprost and one containing treprostinil.

[0033] In some embodiments, iloprost and treprostinil can be administered in a single composition comprising (a) iloprost or a pharmaceutically acceptable salt thereof and (b) treprostinil, its prodrug, its pharmaceutically acceptable salt or a pharmaceutically acceptable salt of its prodrug. Although the present invention is not bound by any theory, the inventors have found that treprostinil can play a stabilizing role when combined with iloprost in the same composition compared to the stability of iloprost when it is not combined with treprostinil in the composition. In some embodiments, this single composition can be a solution comprising (a) iloprost or a pharmaceutically acceptable salt thereof and (b) treprostinil, its prodrug, its pharmaceutically acceptable salt or a pharmaceutically acceptable salt of its prodrug. The concentration of treprostinil in this solution can vary. In some embodiments, the concentration of treprostinil can be 200 μg / ml to 2000 μg / ml, or 300 μg / ml to 1500 μg / ml, or 400 μg / ml to 1200 μg / ml, or any value or sub-range within these ranges. For example, in a certain embodiment, the concentration of treprostinil can be 600 μg / ml. The concentration of iloprost in this solution can vary. In some embodiments, the concentration of iloprost can be 5 μg / ml to 50 μg / ml, or 5 μg / ml to 40 μg / ml, or 5 μg / ml to 30 μg / ml, or any value or sub-range within these ranges. For example, in a certain embodiment, the concentration of iloprost can be 10 μg / ml or 20 μg / ml.

[0034] In some embodiments, the composition comprising (a) iloprost or a pharmaceutically acceptable salt thereof and (b) treprostinil, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof can be administered by oral inhalation or nasal inhalation. In some embodiments, the composition comprising (a) iloprost or a pharmaceutically acceptable salt thereof and (b) treprostinil, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof can be administered by an inhalation device, such as a nebulizer. In some embodiments, the composition comprising (a) iloprost or a pharmaceutically acceptable salt thereof and (b) treprostinil, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof can be administered, for example, by a pulse inhalation device, such as a metered dose inhaler and / or a pulse nebulizer. Pulsatile inhalation devices are disclosed, for example, in U.S. Patent Application Publication No. 20080200449, U.S. Patent Nos. 9,358,240; 9,339,507; 10,376,525; and 10,716,793, each of which is incorporated herein by reference in its entirety.

[0035] In some embodiments, a composition comprising (a) iloprost or a pharmaceutically acceptable salt thereof and (b) treprostinil, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof can be administered as a dry powder composition. The dry powder composition can be administered by a dry powder inhaler, which can be a pulse dry powder inhaler. Dry powder inhalers are disclosed in, for example, U.S. Patent Nos. 7,305,986, 7,464,706, 8,499,757, and 8,636,001, PCT Publication WO2019237028, each of which is incorporated herein by reference.

[0036] In some embodiments, the Diskus can comprise a filter core containing a dry powder composition, which can be a replaceable filter core. In some embodiments, the Diskus can be a breath-actuated inhaler, which can be compact, reusable or disposable. The Diskus can have many different shapes and sizes, and can comprise an airflow conduit pathway system for effectively and rapidly delivering powder medicine to the lungs and / or systemic circulation.

[0037] In some embodiments, in addition to (a) iloprost or a pharmaceutically acceptable salt thereof and (b) treprostinil, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof, the dry powder composition may further comprise a diketopiperazine, such as (E)-3,6-bis[4-(N-carbonyl-2-propenyl)aminobutyl]-2,5-diketopiperazine (FDKP).

[0038] Patients treated with the methods described herein may be treated with other therapies. In some embodiments, the subject will receive background therapy for PH, and on this basis, a combination of treprostinil and iloprost will be added. For example, a combination of iloprost and treprostinil can be added to existing therapy to address acute symptoms, such as symptoms caused by exercise. Background therapy may include phosphodiesterase-5 inhibitors (such as sildenafil and tadalafil), soluble guanylate cyclase stimulators (sGCS) (such as riociguat), endothelin receptor antagonists (ERA) (such as bosentan and ambrisentan) or other prostacyclins.

[0039] In some embodiments, iloprost and treprostinil can be in a single pharmaceutical formulation. In some embodiments, the pharmaceutical formulation can be a liquid formulation. In some embodiments, the pharmaceutical formulation (such as a liquid pharmaceutical formulation) can be an inhalable pharmaceutical formulation, i.e., a formulation administered by inhalation.

[0040] The concentration of treprostinil in a pharmaceutical preparation (such as a liquid pharmaceutical preparation) can vary. In some embodiments, the concentration of treprostinil can be 200 μg / ml to 2000 μg / ml, or 300 μg / ml to 1500 μg / ml, or 400 μg / ml to 1200 μg / ml, or any value or sub-range within these ranges. For example, in a certain embodiment, the concentration of treprostinil can be 600 μg / ml. The concentration of iloprost in a pharmaceutical preparation (such as a liquid pharmaceutical preparation) can vary. In some embodiments, the concentration of iloprost can be 5 μg / ml to 50 μg / ml, or 5 μg / ml to 40 μg / ml, or 5 μg / ml to 30 μg / ml, or any value or sub-range within these ranges. For example, in a certain embodiment, the concentration of iloprost can be 10 μg / ml or 20 μg / ml.

[0041] In some embodiments, in addition to iloprost and treprostinil, the pharmaceutical preparation (such as a liquid pharmaceutical preparation) may also include a buffer. In some embodiments, the buffer may be a phosphate buffer, such as a sodium phosphate buffer. For example, in some embodiments, the preparation may include about 5-15mM sodium phosphate buffer, more preferably about 9-11mM sodium phosphate buffer, and most preferably about 10mM sodium phosphate buffer.

[0042] In some embodiments, the pharmaceutical preparation (such as a liquid pharmaceutical preparation) may also include a salt. For example, the salt may be an alkali metal halide, such as sodium chloride or sodium iodide. For example, in some embodiments, the preparation may include about 20mM to 1000mM, or about 50mM to about 500mM, or about 100mM to about 200mM, or about 115mM to about 125mM.

[0043] In some embodiments, the pharmaceutical formulation (eg, liquid pharmaceutical formulation) can be an isotonic solution.

[0044] In some embodiments, the pharmaceutical formulation (such as a liquid pharmaceutical formulation) can have a pH of about 5.8 to about 7.2, or about 5.9 to about 7.1, or about 6.0 to about 7.0, or about 6.1 to about 6.9, or about 6.2 to about 6.8, or about 6.5.

[0045] In some embodiments, the drug formulation (such as a liquid drug formulation) can have an osmotic pressure of about 200 mOsm / kg to about 500 mOsm / kg, or about 250 mOsm / kg to about 400 mOsm / kg, or about 270 mOsm / kg to about 340 mOsm / kg.

[0046] In some embodiments, the pharmaceutical preparation (such as a liquid pharmaceutical preparation) may include ilorpost itself or a pharmaceutically acceptable salt thereof, such as a tromethamine salt. In some embodiments, the pharmaceutical preparation (such as a liquid pharmaceutical preparation) may include treprostinil as a free base or a pharmaceutically acceptable salt thereof, such as a sodium salt.

[0047] The pharmaceutical preparation (e.g., liquid pharmaceutical preparation) can be used to treat pulmonary hypertension by administering to a subject (e.g., a human). In some embodiments, the pharmaceutical preparation, such as a liquid pharmaceutical preparation, can be administered by inhalation. In some embodiments, pulmonary hypertension can be pulmonary arterial hypertension. In some embodiments, pulmonary hypertension can be pulmonary hypertension associated with interstitial lung disease.

[0048] In some embodiments, the administration of a pharmaceutical formulation (such as a liquid pharmaceutical formulation) can be performed in a single administration event or a single dose event. In some embodiments, the number of breaths in a single administration event or a single dose event may not exceed 20 breaths (or inhalations) or 19 breaths (or inhalations) or 18 breaths (or inhalations) or 17 breaths (or inhalations) or 16 breaths (or inhalations) or 15 breaths (or inhalations) or 14 breaths (or inhalations) or 13 breaths (or inhalations) or 12 breaths (or inhalations) or 11 breaths (or inhalations) or 10 breaths (or inhalations) or 9 breaths (or inhalations) or 8 breaths (or inhalations) or 7 breaths (or inhalations) or 6 breaths (or inhalations) or 5 breaths (or inhalations) or 4 breaths (or inhalations) or 3 breaths (or inhalations) or 2 breaths (or inhalations) or 1 breath (or inhalation).

[0049] In some embodiments, a single event of administering a drug formulation (eg, a liquid drug formulation) can be less than about 10, 7, 5, 3, 2, or 1 minute.

[0050] The number of single administration events of a pharmaceutical formulation (such as a liquid pharmaceutical formulation) administered by inhalation per day can vary. For example, the number of single administration events per day can be 1, 2, 3, 4, 5, or 6 times per day. In some embodiments, the number of single administration events per day can be at least twice, such as 2 to 5 times per day or 2 to 3 times per day.

[0051] In some embodiments, the pharmaceutical preparation (e.g., liquid pharmaceutical preparation) can be administered, for example, by a pulse inhalation device, such as a metered dose inhaler and / or a pulse nebulizer. Pulse inhalation devices are disclosed, for example, in U.S. Patent Application Publication No. 20080200449, U.S. Patent Nos. 9,358,240, 9,339,507; 10,376,525; and 10,716,793, the entire contents of each of which are incorporated herein by reference.

[0052] In a single administration event of a pharmaceutical preparation (such as a liquid pharmaceutical preparation), the dose or amount of iloprost or a pharmaceutically acceptable salt thereof administered by inhalation may vary. In some embodiments, the single administration event dose of iloprost may be at least 2 μg or at least 2.5 μg. In some embodiments, the single administration event dose of iloprost may be 2 μg to 10 μg, or 2 μg to 9 μg, or 2.5 μg to 5 μg, or any value or sub-range within these ranges. In some embodiments, in all administration events of a day, the daily dose of iloprost administered may be less than 15 μg, or not more than or less than 14 μg, or not more than or less than 13 μg, or not more than or less than 12 μg, or not more than or less than 11 μg, or not more than or less than 10 μg, or not more than or less than 9 μg, or not more than or less than 8 μg, or not more than or less than 7 μg, or not more than or less than 6 μg, or not more than or less than 5 μg.

[0053] In a single administration event of a pharmaceutical preparation (such as a liquid pharmaceutical preparation), the dosage or amount of treprostinil, its prodrug, its pharmaceutically acceptable salt, or its pharmaceutically acceptable salt of its prodrug administered by inhalation can vary. In some embodiments, the single administration event dose of treprostinil can be at least 5 μg or at least 6 μg. In some embodiments, the single administration event dose of treprostinil can be 5 μg to 120 μg, or 18 μg to 120 μg, or 6 μg to 96 μg, or 7.5 μg to 100 μg, or 10 μg to 100 μg, or 15 μg to 100 μg, or 15 μg to 90 μg, or 15 μg to 75 μg, or 30 μg to 75 μg, or any value or sub-range within these ranges.

[0054] In some embodiments, a drug formulation (eg, a liquid drug formulation) can be administered on demand (ie, as needed) to a patient experiencing at least one undesirable symptom of pulmonary hypertension (eg, dyspnea or shortness of breath).

[0055] The stability of iloprost in a pharmaceutical formulation (eg, a liquid pharmaceutical formulation) containing both iloprost and treprostinil may be greater than the stability of iloprost in an otherwise identical iloprost formulation that does not contain treprostinil.

[0056] The pharmaceutical preparation (such as liquid pharmaceutical preparation) containing both iloprost and treprostinil can be a preparation with storage stability, which can be a freshly prepared preparation. Preferably, the preparation can be stored or stored for at least 18 months, more preferably at least 24 months of storage period. In some embodiments, the preparation can be stored or stored for at least two weeks, or at least one month, or at least 6 weeks, or at least two months, or at least 10 weeks, or at least three months, or two weeks to three months, or one month to three months, or one month to two months. In some embodiments, preferably, the amount of iloprost in the preparation after storage is at least 90% of the amount of iloprost in the preparation before storage, or at least 91%, or at least 92%, or at least 93%, or at least 94%. In some embodiments, this storage can be carried out without cooling the preparation to a temperature below about 20C. For example, in some embodiments, it can be stored at a temperature of about 20C to about 50C, or about 22C to about 45C, or about 25C to about 40C.

[0057] In some embodiments, pharmaceutical preparations (such as liquid pharmaceutical preparations) can be stored in containers. In some embodiments, the container can be a sealed container. In some embodiments, the container can be a vial or an ampoule. In some embodiments, the container can be a glass container, i.e., a container made of glass. In some embodiments, the container can be a plastic container, i.e., a container made of plastic. Non-limiting examples of plastics include polyolefins, such as polypropylene and polyethylene, such as low-density polyethylene (LDPE). In some embodiments, the container is equipped with a removable cover that can be opened and closed, such as a rubber sealing cover connected to a glass container.

[0058] Also provided is the dosage form of the pharmaceutical preparation (such as liquid pharmaceutical preparation) in the container.In some embodiments, the dosage form can be a dosage form for inhalation.In some embodiments, the container can be a sealed container.In some embodiments, the container can be a vial or an ampoule.In some embodiments, the container can be a glass container, i.e. a container made of glass.In some embodiments, the container can be a plastic container, i.e. a container made of plastic.The non-limiting examples of plastics include polyolefins, such as polypropylene and polyethylene, such as low-density polyethylene (LDPE).The amount of the pharmaceutical preparation (such as liquid pharmaceutical preparation) in the container can vary.In some embodiments, the container can contain 0.5ml to 50ml, or 1ml to 30ml, or 2ml to 20ml of liquid pharmaceutical preparation.

[0059] The embodiments described herein are further illustrated, but not limited, by the following working examples. Example Example 1 Development of Iloprost and Treprostinil Formulations

[0060] The purpose of this example is to describe the formulation development work for an inhalation formulation of iloprost and treprostinil.An isotonic formulation with a pH of 6.5 was developed. Table 1. Definitions the term definition ACN Acetonitrile HPLC High performance liquid chromatography <![CDATA[H3PO4]]> Phosphoric acid NaCl Sodium chloride UV UV rays program Solubility assessment

[0061] The solubility of iloprost at 100 μg / mL was evaluated at five different pH levels by visual inspection and HPLC-UV analysis. A stock solution of 1 mg / mL of iloprost was prepared in ethanol. The stock solution was diluted 10 times in each buffer and mixed thoroughly. The buffer solution was visually inspected for precipitation. Before being analyzed by HPLC, the buffer solution was filtered with a 0.45 μm nylon filter. The buffer and the associated pH are shown in Table 2. The HPLC conditions for solubility analysis are shown in Table 3. Table 2. Buffers and associated pH. Buffer Measured pH 10 mM citrate 2.89 10 mM acetate 5 10 mM phosphate 6.23 10 mM phosphate 7.27 10 mM phosphonate 8.60 Table 3. HPLC conditions for solubility analysis. Formulation Development Development of Iloprost Preparations

[0062] Iloprost formulations were prepared at 10 μg / mL with two different NaCl concentrations. A 5 mg / mL iloprost stock solution was prepared in ethanol and diluted 500-fold in the formulations. The formulations were buffered with 10 mM sodium phosphate buffer at pH 6.5. NaCl was added to a final salt concentration of 115 mM and 125 mM. The osmotic pressure of the formulations was evaluated. Development of Iloprost and Treprostinil Formulations

[0063] Two formulations of iloprost and treprostinil were prepared, with iloprost at 10 μg / mL and treprostinil at 600 μg / mL. A 5 mg / mL stock solution of iloprost was prepared in ethanol and diluted 500-fold in the formulation. Treprostinil was quantitatively weighed into the formulation. The formulation was buffered with 10 mM sodium phosphate buffer with two different NaCl concentrations (115 mM and 125 mM). After the addition of treprostinil, 3-4 drops of 1N NaOH were added to dissolve the treprostinil in the buffer. The pH was further adjusted so that the pH of the formulation was within 0.5 of the 6.5 target. The osmotic pressure of the formulation was evaluated.

[0064] Two formulations of iloprost and treprostinil were prepared, with iloprost at 20 μg / mL and treprostinil at 600 μg / mL. A 5 mg / mL stock solution of iloprost was prepared in ethanol and diluted 250 times in the formulation. Treprostinil was quantitatively weighed into the formulation. The formulation was buffered with 10 mM sodium phosphate buffer with two different NaCl concentrations (115 mM and 125 mM). After the addition of treprostinil, 3-4 drops of 1N NaOH were added to dissolve the treprostinil in the buffer. The pH was further adjusted so that the pH of the formulation was within 0.5 of the 6.5 target. The osmotic pressure of the formulation was evaluated. Results and Discussion Solubility assessment

[0065] No visible solubility issues were found. The visible observations and pH are shown in Table 4. The figure shows the chromatograms of five different buffer solutions containing 100 μg / mL of iloprost. Although no visible particles were found, the chromatographic analysis indicated that there may be solubility issues below pH 6. Table 4. Physical observations and pH of iloprost buffer solutions. Buffer Initial pH Final pH observe 10 mM citrate 2.89 2.99 Colorless, no visible particulate matter 10mM Acetate 5.00 5.08 Colorless, no visible particulate matter 10 mM phosphate 6.23 6.36 Colorless, no visible particulate matter 10 mM phosphate 7.27 7.42 Colorless, no visible particulate matter 10 mM phosphate 8.60 8.59 Colorless, no visible particulate matter Formulation Development Development of Iloprost Preparations

[0066] Both 115 mM and 125 mM salt concentrations are within the isotonic range. The 125 mM formulation is closer to the target of 290 mOsm / kg. Table 5 summarizes the formulations and osmolarities. Table 5. Iloprost formulations and osmolarities. preparation Measured pH Measured osmotic pressure (mOsm / kg) 10 μg / mL iloprost, pH 6.5, 115 mM NaCl 6.45 272 10 μg / mL iloprost, pH 6.5, 125 mM NaCl 6.45 290 Development of Iloprost and Treprostinil Formulations

[0067] Treprostinil requires the addition of base to dissolve in the formulation buffer. Additional pH adjustment results in an increase in the ions present. The 125 mM salt level in the second formulation (20 μg / mL iloprost and 600 μg / mL treprostinil) combined with additional pH adjustment resulted in an osmotic pressure close to the upper end of the isotonic range. The 115 mM salt level is best suited to keep the formulation in the middle of the isotonic solution range. Table 6 summarizes the formulations and osmotic pressures. Table 6. Iloprost and treprostinil formulations and osmolality. in conclusion

[0068] Iloprost formulations were developed at 10 μg / mL in 10 mM sodium phosphate buffer at pH 6.5 containing 125 mM NaCl. Two formulations containing iloprost (10 and 20 μg / mL) and 600 μg / mL of treprostinil were developed in 10 mM sodium phosphate buffer at pH 6.5 containing 115 mM NaCl. Example 2 Stability testing of iloprost formulations Table 7: Summary of stability testing of 10 μg / mL iloprost, pH 6.5, 125 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 5 mL glass vial, sample orientation: inverted 1 Results were confirmed by reinjection and reloading into vials. Table 8: Summary of single impurities of 10 μg / mL iloprost, pH 6.5, 125 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 5 mL glass vial Report the percent adjusted area of all impurities with RRT and ≥ 0.05% adjusted area ND = Not detected (< LOD). LOD represents "limit of detection". NR = Not reported (≥ LOD and < 0.05%) NT = Not tested Table 9: Summary of stability testing of 10 μg / mL iloprost, pH 6.5, 125 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 5 mL glass vial, sample orientation: inverted Table 10: Summary of single impurities of 10 μg / mL iloprost, pH 6.5, 125 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 5 mL glass vial Report the percent adjusted area of all impurities with RRT and ≥ 0.05% adjusted area ND = Not detected (< LOD) NR = Not reported (≥ LOD and < 0.05%) NT = Not tested Table 11: Summary of stability testing of 10 μg / mL iloprost, pH 6.5, 125 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 3 mL LDPE ampoule 1 The two injected samples differed by -4%. Table 12: Summary of single impurities of 10 μg / mL iloprost, pH 6.5, 125 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 3 mL LDPE ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 13: Summary of stability testing of 10 μg / mL iloprost, pH 6.5, 125 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 3 mL LDPE ampoule Table 14: Summary of Single Impurities of 10 μg / mL Iloprost, pH 6.5, 125 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Example 3 Stability test of iloprost / treprostinil formulation 1 Table 15: Summary of stability testing of 10 μg / mL iloprost, 600 μg / mL treprostinil, pH 6.5, 115 mM NaCl, at 25 ± 2°C / 60 ± 5% RH, 5 mL glass vials. Sample orientation inverted Table 16A: Iloprost Impurity Summary for 10 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 25 ± 2°C / 60 ± 5% RH, 5 mL Glass Vial Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 16B: Treprostinil Impurity Summary for 10 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 25±2°C / 60±5% RH, 5 mL Glass Vial Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 17: Summary of stability testing of 10 μg / mL iloprost, 600 μg / mL treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 5 mL glass vial, sample orientation: inverted Table 18A: Iloprost Impurity Summary for 10 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2°C / 75 ± 5% RH, 5 mL Glass Vial Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 18B: Treprostinil Impurity Summary for 10 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 5 mL Glass Vial Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 19: Summary of stability testing of 10 μg / mL iloprost, 600 μg / mL treprostinil, pH 6.5, 115 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 3 mL LDPE ampoule Table 20A: Iloprost Impurity Summary for 10 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 25±2°C / 60±5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 20B: Treprostinil Impurity Summary for 10 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 25±2°C / 60±5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 21: Summary of stability testing of 10 μg / mL iloprost, 600 μg / mL treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 3 mL LDPE ampoule Table 22A: Iloprost Impurity Summary for 10 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2°C / 75 ± 5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 22B: Treprostinil Impurity Summary for 10 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2°C / 75 ± 5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Example 4 Stability test of iloprost / treprostinil formulation 2 Table 23: Summary of stability testing of 20 μg / mL iloprost, 600 μg / mL treprostinil, pH 6.5, 115 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 5 mL glass vial, sample orientation: inverted Table 24A: Iloprost Impurity Summary for 20 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 5 mL Glass Vial Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 24B: Treprostinil Impurity Summary for 20 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 5 mL Glass Vial Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 25: Summary of stability testing of 20 μg / mL iloprost, 600 μg / mL treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 5 mL glass vial, sample orientation: inverted Table 26A: Iloprost Impurity Summary for 20 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2°C / 75 ± 5% RH, 5 mL Glass Vial Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 26B: Treprostinil Impurity Summary for 20 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 5 mL Glass Vial Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 27: Summary of stability testing of 20 μg / mL iloprost, 600 μg / mL treprostinil, pH 6.5, 115 mM NaCl, at 25 ± 2 °C / 60 ± 5% RH, 3 mL LDPE ampoule Table 28A: Iloprost Impurity Summary for 20 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 25±2°C / 60±5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 28B: Treprostinil Impurity Summary for 20 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 25±2°C / 60±5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 29: Summary of stability testing of 20 μg / mL iloprost, 600 μg / mL treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2 °C / 75 ± 5% RH, 3 mL LDPE ampoule Table 30A: Iloprost Impurity Summary for 20 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2°C / 75 ± 5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested Table 30B: Treprostinil Impurity Summary for 20 μg / mL Iloprost, 600 μg / mL Treprostinil, pH 6.5, 115 mM NaCl, at 40 ± 2°C / 75 ± 5% RH, 3 mL LDPE Ampoule Report RRT and adjusted area percentage for all impurities ≥ 0.05% adjusted area ND=Not Detected( <LOD) NR = Not reported (≥LOD and <0.05%) NT = Not Tested in conclusion

[0069] The stability test results in Examples 2-4 show that surprisingly, the stability of iloprost in Formulations 1 and 2 containing treprostinil in Examples 3 and 4 is higher than that of Formulation 2 without treprostinil. Without being bound by any theory, these results may indicate that in Formulations 1 and 2 of Examples 3 and 4, the iloprost molecules may be attached to the treprostinil molecules. ***

[0070] Although the above mentioned is a specific preferred embodiment, it is to be understood that the present invention is not limited thereto. For those skilled in the art, various modifications can be made to the disclosed embodiments, and these modifications are within the scope of the present invention.

[0071] All publications, patent applications, and patents cited in this specification are incorporated herein by reference in their entirety.

Claims

1. A method for treating pulmonary hypertension, comprising administering iloprost or a pharmaceutically acceptable salt thereof and treprostinil or a pharmaceutically acceptable salt thereof to a subject in need thereof by inhalation.

2. The method of claim 1, wherein iloprost or a pharmaceutically acceptable salt thereof and treprostinil or a pharmaceutically acceptable salt thereof are administered together in a single dosage event.

3. The method according to claim 1 or 2, wherein iloprost or a pharmaceutically acceptable salt thereof and treprostinil or a pharmaceutically acceptable salt thereof are administered within one minute or less.

4. The method according to any one of the preceding claims, wherein the administering comprises administering to the subject a composition comprising iloprost or a pharmaceutically acceptable salt thereof and treprostinil or a pharmaceutically acceptable salt thereof.

5. The method of claim 4, wherein the composition is a dry powder composition.

6. The method according to any one of the preceding claims, wherein the iloprost or a pharmaceutically acceptable salt thereof is iloprost or the tromethamine salt of iloprost.

7. The method according to any one of the preceding claims, wherein treprostinil or a pharmaceutically acceptable salt thereof is treprostinil or the sodium salt of treprostinil.

8. The method according to any one of the preceding claims, wherein iloprost or a pharmaceutically acceptable salt thereof is administered at a dose of at least 2.5 μg.

9. The method of claim 8, wherein iloprost or a pharmaceutically acceptable salt thereof is administered at a dose of 2.5 μg to 5 μg.

10. The method according to any one of the preceding claims, wherein treprostinil or a pharmaceutically acceptable salt thereof is administered in a dose of at least 5 μg.

11. The method of claim 10, wherein treprostinil or a pharmaceutically acceptable salt thereof is administered at a dose of 6 μg to 96 μg.

12. The method of claim 10, wherein treprostinil or a pharmaceutically acceptable salt thereof is administered at a dose of 5 μg to 120 μg.

13. The method of claim 10, wherein treprostinil or a pharmaceutically acceptable salt thereof is administered at a dose of 18 μg to 120 μg.

14. The method according to any one of the preceding claims, wherein the administration is carried out in at least two administration events per day.

15. The method according to any one of the preceding claims, wherein the administration is carried out in at least three administration events per day.

16. The method of any one of the preceding claims, wherein a single event of administration is three breaths or less.

17. The method according to any one of the preceding claims, wherein the administration is performed on demand.

18. The method of claim 17, wherein the administering is performed when the subject develops at least one undesirable symptom of pulmonary hypertension.

19. The method of claim 18, wherein the administering is performed when the subject experiences dyspnea.

20. The method according to any one of the preceding claims, wherein the pulmonary hypertension is pulmonary arterial hypertension.

21. The method of any one of claims 1-19, wherein the pulmonary hypertension is pulmonary hypertension associated with interstitial lung disease.

22. A method for treating pulmonary hypertension comprising administering to a subject in need thereof a composition comprising: (i) iloprost or a pharmaceutically acceptable salt thereof and (ii) treprostinil or a pharmaceutically acceptable salt thereof in a single event dose by inhalation, wherein the dose of iloprost or a pharmaceutically acceptable salt thereof delivered to the subject is at least 2.5 μg, and wherein the dose of treprostinil or a pharmaceutically acceptable salt thereof delivered to the subject is at least 5 μg.

23. The method of claim 22, wherein the composition is a dry powder.

24. The method of claim 22 or 23, wherein the administering is performed using a dry powder inhaler.

25. The method of claim 22, wherein the administering is performed using a nebulizer.

26. The method of any one of claims 22-25, wherein the single event dose is administered in three or fewer breaths.

27. The method according to any one of claims 22-25, wherein the administration is performed within 3 minutes.

28. The method of claim 27, wherein the administering is performed in one minute or less.

29. The method of any one of claims 22-28, wherein the administration is performed in a single breath.

30. The method of any one of claims 22-29, wherein the composition comprises (i) iloprost or iloprost tromethamine and (ii) treprostinil or treprostinil sodium.

31. The method of any one of claims 22-30, wherein the administration is performed in at least two administration events per day, each of the at least two administration events comprising administering a single event dose of the composition.

32. The method of claim 31 , wherein the at least two administration events comprise two or three administration events per day.

33. The method of claim 31 , wherein the at least two administration events comprise two to five administration events per day.

34. The method of any one of claims 22-33, wherein the administering is performed on demand.

35. The method of any one of claims 22-34, wherein the pulmonary hypertension is pulmonary arterial hypertension.

36. The method of any one of claims 22-34, wherein the pulmonary hypertension is pulmonary hypertension associated with interstitial lung disease.

37. A pharmaceutical preparation comprising iloprost or a pharmaceutically acceptable salt thereof and treprostinil or a pharmaceutically acceptable salt thereof.

38. The pharmaceutical preparation according to claim 37, which is a liquid preparation.

39. The pharmaceutical formulation according to claim 36 or 37, which is an inhalable formulation.

40. The pharmaceutical formulation according to any one of claims 37-39, wherein the concentration of iloprost in the formulation is 5 μg / ml to 50 μg / ml.

41. The pharmaceutical formulation according to claim 40, wherein the concentration of iloprost is 10 μg / ml to 20 μg / ml.

42. The pharmaceutical formulation according to any one of claims 37-41, wherein the concentration of treprostinil in the formulation is 200 μg / ml to 2000 μg / ml.

43. The pharmaceutical formulation of claim 42, wherein the concentration of treprostinil is about 600 μg / ml.

44. The pharmaceutical formulation of any one of claims 37-43, wherein the formulation further comprises a buffer.

45. The pharmaceutical formulation of claim 44, wherein the buffer comprises a sodium phosphate buffer.

46. ​​The pharmaceutical formulation of any one of claims 37-45, wherein the formulation further comprises about 10 mM sodium phosphate buffer.

47. The pharmaceutical formulation of any one of claims 37-46, wherein the formulation further comprises a salt.

48. The pharmaceutical formulation of claim 47, wherein the salt is sodium chloride.

49. The pharmaceutical formulation of any one of claims 37-48, wherein the formulation further comprises about 100 mM to 150 mM sodium chloride.

50. The pharmaceutical formulation of claim 49, wherein the formulation comprises 115 mM to 125 mM sodium chloride.

51. The pharmaceutical formulation of any one of claims 37-50, wherein the formulation is an isotonic solution.

52. The pharmaceutical formulation of any one of claims 37-51, having a pH of about 6.0 to 7.

0.

53. The pharmaceutical formulation of claim 52, which has a pH of about 6.

5.

54. The pharmaceutical formulation of any one of claims 37-53, wherein the formulation has an osmotic pressure of 250 to 400 mOsm / kg.

55. The pharmaceutical formulation of claim 54, wherein the osmotic pressure is 270 mOsm / kg to 340 mOsm / kg.

56. The pharmaceutical formulation according to any one of claims 37-55, wherein iloprost or a pharmaceutically acceptable salt thereof is iloprost or a tromethamine salt of iloprost.

57. The pharmaceutical formulation of any one of claims 37-56, wherein the treprostinil or a pharmaceutically acceptable salt thereof is treprostinil or a sodium salt of treprostinil.

58. A method of treating pulmonary hypertension comprising administering by inhalation to a subject in need thereof a pharmaceutical formulation according to any one of claims 37-57.

59. The method of claim 58, wherein a single event of administration occurs in one minute or less.

60. The method of claim 58 or 59, wherein the administering is performed using a nebulizer.

61. The method of any one of claims 58-60, wherein iloprost or a pharmaceutically acceptable salt thereof is administered at a dose of at least 2.5 μg.

62. The method of claim 61, wherein iloprost or a pharmaceutically acceptable salt thereof is administered at a dose of 2.5 μg to 5 μg.

63. The method of any one of claims 58-62, wherein treprostinil or a pharmaceutically acceptable salt thereof is administered at a dose of at least 5 μg.

64. The method of claim 63, wherein treprostinil or a pharmaceutically acceptable salt thereof is administered at a dose of 6 μg to 96 μg.

65. The method of claim 63, wherein treprostinil or a pharmaceutically acceptable salt thereof is administered at a dose of 5 μg to 120 μg.

66. The method of claim 63, wherein treprostinil or a pharmaceutically acceptable salt thereof is administered at a dose of 18 μg to 120 μg.

67. The method of any one of claims 58-66, wherein the administration is performed in at least two administration events per day.

68. The method of any one of claims 58-67, wherein the administration is performed in at least three administration events per day.

69. The method of any one of claims 58-68, wherein a single event of administration is three or fewer breaths.

70. The method of any one of claims 58-69, wherein the administering is performed on demand.

71. The method of claim 70, wherein the administering is performed when the subject develops at least one undesirable symptom of pulmonary hypertension.

72. The method of claim 71, wherein the administering is performed when the subject experiences dyspnea.

73. The method of any one of claims 58-72, wherein the pulmonary hypertension is pulmonary arterial hypertension.

74. The method of any one of claims 58-72, wherein the pulmonary hypertension is pulmonary hypertension associated with interstitial lung disease.

75. The method of any one of claims 58-74, further comprising preparing the pharmaceutical formulation; storing the prepared pharmaceutical formulation for a storage period of at least one month after preparation, and wherein the administering is performed after said storage.

76. The method of claim 75, wherein the storage period is at least 2 months.

77. The method of claim 75 or 76, wherein the pharmaceutical formulation is stored in a container during the storage period.

78. The method of claim 77, wherein the container is a glass container.

79. The method of claim 77, wherein the container is a plastic container.

80. The method of any one of claims 75-79, wherein the storing is performed at a temperature of 20°C to 45°C.

81. The method of any one of claims 75-80, wherein the amount of iloprost in the formulation after storage is at least 90% of the amount of iloprost in the formulation before storage.

82. A dosage form comprising a dose container and a pharmaceutical formulation according to any one of claims 37-57 in the container.

83. The dosage form of claim 82, wherein the container is a glass container.

84. The dosage form of claim 82, wherein the container is a plastic container.

Citation Information

Patent Citations

  • Treprostinil administration using a metered dose inhaler

    CN101495122A

  • Methods of treating PAH with combinations of ralinepag and other agents

    CN110691612A

  • Treprostinil administration using a metered dose inhaler

    US20080200449A1

  • Prostacylin compositions and methods for using the same

    WO2015138423A1